{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(7)"],"submitter":["Tsuriya D"],"pubmed_abstract":["<h4>Aim</h4>The favor effect on liver disease by odium-glucose cotransporter inhibitor (SGLT2i) and GLP-1 receptor agonist (GLP1Ra) was reported; however, the effect of the combination treatment of these drugs was not well known.<h4>Methods</h4>We retrospectively analyzed data for 643 patients with type 2 diabetes receiving SGLT2i + GLP1Ra combination treatment for at least 1 year (331 and 312 patients in the GLP1Ra- and SGLT2i-preceding groups, respectively). Propensity score (PS) matching was used to compare the effects of the preceding drugs on liver function.<h4>Results</h4>The mean AST and ALT values at baseline, at the initiation of combination treatment, and at final observation were 29.8 ± 20.0 and 37.7 ± 29.5, 28.7 ± 17.3 and 35.3 ± 6.0, 26.0 ± 14.6 and 30.1 ± 21.6 IU/L, respectiv"],"journal":["Journal of diabetes investigation"],"pagination":["1243-1253"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12209503"],"repository":["biostudies-literature"],"pubmed_title":["Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)."],"pmcid":["PMC12209503"],"pubmed_authors":["Tsukamoto S","Toyoda M","Muta Y","Tsuriya D","Takashi Y","Tamura K","Kawanami D","Kobayashi K","Kimura M","Hashimoto T","Yokomizo H","Kanasaki K","Takeshita K"],"additional_accession":[]},"is_claimable":false,"name":"Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study).","description":"<h4>Aim</h4>The favor effect on liver disease by odium-glucose cotransporter inhibitor (SGLT2i) and GLP-1 receptor agonist (GLP1Ra) was reported; however, the effect of the combination treatment of these drugs was not well known.<h4>Methods</h4>We retrospectively analyzed data for 643 patients with type 2 diabetes receiving SGLT2i + GLP1Ra combination treatment for at least 1 year (331 and 312 patients in the GLP1Ra- and SGLT2i-preceding groups, respectively). Propensity score (PS) matching was used to compare the effects of the preceding drugs on liver function.<h4>Results</h4>The mean AST and ALT values at baseline, at the initiation of combination treatment, and at final observation were 29.8 ± 20.0 and 37.7 ± 29.5, 28.7 ± 17.3 and 35.3 ± 6.0, 26.0 ± 14.6 and 30.1 ± 21.6 IU/L, respectiv","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-06-05T07:30:32.036Z","creation":"2026-05-14T03:12:26.238Z"},"accession":"S-EPMC12209503","cross_references":{"pubmed":["40331745"],"doi":["10.1111/jdi.70066"]}}